PLx Pharma Winddown 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Pat Lonergan

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	5.7yrs

최근 관리 업데이트

Recent updates

CEO

Pat Lonergan (88 yo)

no data

테뉴어

Mr. Patrick M. Lonergan, also known as Pat, co-founded Numark Laboratories Inc. in 1987 and has been its President since January 1989. Mr. Lonergan serves as Member of Chief Executive Officer Advisory Grou...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Michael Valentino	Chairman	12.1yrs	US$393.75k	1.7% € 91.0
Kirk Calhoun	Independent Director	7.8yrs	US$55.00k	0.0057% € 0.3
Todd Rosengart	Member of Scientific Advisory Board	5.7yrs	데이터 없음	데이터 없음
Robert Casale	Independent Director	7.5yrs	US$75.50k	0.0093% € 0.5
Gary Balkema	Independent Director	7.5yrs	US$50.00k	0.019% € 1.0
P. Steg	Member of Scientific Advisory Board	5.7yrs	데이터 없음	데이터 없음
Deepak Bhatt	Member of Scientific Advisory Board	5.7yrs	데이터 없음	데이터 없음
Byron Cryer	Member of Scientific Advisory Board	5.7yrs	데이터 없음	데이터 없음
Jayne Prats	Member of Scientific Advisory Board	5.7yrs	데이터 없음	데이터 없음
Efthymios Deliargyris	Member of Scientific Advisory Board	3.3yrs	US$801.65k	데이터 없음
Dominick Angiolillo	Member of Scientific Advisory Board	5.7yrs	데이터 없음	데이터 없음
Carey Kimmelstiel	Member of Scientific Advisory Board	5.7yrs	데이터 없음	데이터 없음

5.7yrs

평균 재임 기간

66.5yo

평균 연령

경험이 풍부한 이사회: 1D5A 의 이사회는 경험(평균 재직 기간 5.7 년)으로 간주됩니다.

PLx Pharma Winddown 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Plx Pharma Winddown Corp. Announces Executive Changes

Insufficient new directors

PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of Board

PLx Pharma Inc., Annual General Meeting, Nov 08, 2022

Key Executive recently bought €46k worth of stock

Key Executive recently bought €46k worth of stock

Recent updates

PLx Pharma Winddown Corp. Files Form 15

Plx Pharma Winddown Corp. Announces Executive Changes

Insufficient new directors

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC

PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of Board

PLx Pharma Inc. to Report Q3, 2022 Results on Nov 11, 2022

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

PLx Pharma Inc., Annual General Meeting, Nov 08, 2022

PLx Pharma Inc. to Report Q2, 2022 Results on Aug 12, 2022

PLx Pharma Inc. to Report Q1, 2022 Results on May 13, 2022

Key Executive recently bought €46k worth of stock

Key Executive recently bought €46k worth of stock

No longer forecast to breakeven

PLx Pharma Inc. to Report Q4, 2021 Results on Mar 11, 2022

PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this Month

PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in August

Plx Pharma Inc.’s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in August

Executive Chairman recently bought €82k worth of stock

Revenue in line with expectations

Executive Chairman recently bought €168k worth of stock

PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million.

PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million.

PLx Pharma Receives FDA Approval of sNDAs for Both Vazalore 325 Mg and 81 Mg

New 90-day high: €6.05

New 90-day high: €5.20

PLx Pharma Inc. announced that it has received $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investors

PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug Administration

PLx Pharma Inc. announced that it expects to receive $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investors

New 90-day high: €3.58

Revenue in line with expectations

PLx Pharma Inc. to Report Q3, 2020 Results on Nov 13, 2020

PLx Pharma Inc. to Report Q2, 2020 Results on Aug 14, 2020

PLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value Index

CEO

테뉴어

이사회 구성원

평균 재임 기간

평균 연령